Patent application number | Description | Published |
20080280917 | Nitrogen-Containing heterocyclyl ketones and methods of use - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 11-13-2008 |
20080312232 | Substituted amide derivatives and methods of use - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 12-18-2008 |
20090124609 | Fused heterocyclic derivatives and methods of use - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 05-14-2009 |
20090124612 | Fused heterocyclic derivatives and methods of use - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 05-14-2009 |
20090318436 | Fused heterocyclic derivatives and methods of use - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 12-24-2009 |
20100160280 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS - Pyridine and pyrimidine compounds: | 06-24-2010 |
20110092504 | INHIBITORS OF PI3 KINASE - The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein Q, X | 04-21-2011 |
20110118252 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 05-19-2011 |
20120070413 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 03-22-2012 |
20120071474 | INHIBITORS OF PI3 KINASE - The present invention relates to compounds of Formula I, II or III or a pharmaceutically acceptable salt thereof; | 03-22-2012 |
20120107275 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 05-03-2012 |
20120148531 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 06-14-2012 |
20130303529 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 11-14-2013 |
Patent application number | Description | Published |
20090006600 | NETWORK IDENTIFICATION AND CONFIGURATION USING NETWORK SIGNATURE - Methods, computer program products, systems and data structures for generating a signature for a network are described. A network signature may include, for example, network information associated with a network (e.g., IP address, MAC address, domain name, DNS name, routing information, phone number, etc.). A signature of a network that has previously been created can be stored to enable identification of the network in the future and to record parameters, settings, properties and attributes previously used for that network. | 01-01-2009 |
20090006635 | Network management - Systems and methods relating to managing network addresses. In one implementation, a method is provided. The method includes sending a first request to use a particular network address, sending one or more second requests for respective hardware addresses corresponding to network addresses of one or more network address leases. When a hardware address corresponding to a particular network address lease is received in response to one of the one or more second requests and an acknowledgement of the first request to use the network address is not received determining whether the network address identified by the lease is the same as the network address in the first request, and when the network address is not the same, sending a third request to use the identified network address corresponding to the lease. | 01-01-2009 |
20090304000 | OUTBOUND TRANSMISSION OF PACKET BASED ON ROUTING SEARCH KEY CONSTRUCTED FROM PACKET DESTINATION ADDRESS AND OUTBOUND INTERFACE - A method is described that involves associating an outbound packet with a first network interface and constructing a search key from an identifier of the first network interface and the outbound packet's destination address. The method further entails submitting the search key to a routing function where the routing function identifies the outbound packet's next hop address. The method also involves transmitting the outbound packet to a node identified by the next hop address from the first network interface. | 12-10-2009 |
20090304001 | SOURCE ADDRESS BASED ROUTING PROCESS - A method is described that entails assigning a source network address to an outbound packet, associating the outbound packet with a network service and identifying a first network interface associated with the network service. The method further entails inquiring into and confirming that the first network interface is associated with the source network address. The method further entails constructing a search key from an identifier of the first network interface and the outbound packet's destination address. The method further entails submitting the search key to a routing function, the routing function providing the outbound packet's next hop address. The method further entails transmitting the outbound packet to a node identified by the next hop address from the network interface. | 12-10-2009 |
20090304005 | ROUTING TABLE LOOKUP ALGORITHM EMPLOYING SEARCH KEY HAVING DESTINATION ADDRESS AND INTERFACE COMPONENT - A routing table lookup algorithm is described that, for a first outbound packet, performs a first route lookup into the routing table with a first search key that includes the first packet's destination address and a first network interface identifier, and, for a second outbound packet, performs a second route lookup into the routing table with a second search key that includes the second outbound packet's destination address but does not include any network interface identifier. | 12-10-2009 |
20090304006 | ROUTING TABLE BUILD ALGORITHM FOR A ROUTING TABLE THAT USES A SEARCH KEY CONSTRUCTED FROM PACKET DESTINATION ADDRESS AND OUTBOUND INTERFACE - A method is described that involves, in view of a first default entry for a first subnet that is reachable through a first network service, where the first default entry has a numeric destination value, and in view of a second default entry for a second subnet that is reachable through a second network service, wherein the second default entry has the numeric destination value, sorting the first and second default entries by deciding that the first network service is ranked higher than the second network service. The method further involves configuring the first default entry within a routing table to have the numeric destination and not an interface component within the first default entry's search term, and, configuring the second default entry within the routing table to have the numeric destination and the second network service's interface component within the second default entry's search term. | 12-10-2009 |
20110222542 | SOURCE ADDRESS BASED ROUTING PROCESS - A method is described that entails assigning a source network address to an outbound packet, associating the outbound packet with a network service and identifying a first network interface associated with the network service. The method further entails inquiring into and confirming that the first network interface is associated with the source network address. The method further entails constructing a search key from an identifier of the first network interface and the outbound packet's destination address. The method further entails submitting the search key to a routing function, the routing function providing the outbound packet's next hop address. The method further entails transmitting the outbound packet to a node identified by the next hop address from the network interface. | 09-15-2011 |
20120057596 | Outbound Transmission Of Packet Based On Routing Search Key Constructed From Packet Destination Address And Outbound Interface - A method is described that involves associating an outbound packet with a first network interface and constructing a search key from an identifier of the first network interface and the outbound packet's destination address. The method further entails submitting the search key to a routing function where the routing function identifies the outbound packet's next hop address. The method also involves transmitting the outbound packet to a node identified by the next hop address from the first network interface. | 03-08-2012 |
20120257608 | ROUTING TABLE LOOKOUP ALGORITHM EMPLOYING SEARCH KEY HAVING DESTINATION ADDRESS AND INTERFACE COMPONENT - A routing table lookup algorithm is described that, for a first outbound packet, performs a first route lookup into the routing table with a first search key that includes the first packet's destination address and a first network interface identifier, and, for a second outbound packet, performs a second route lookup into the routing table with a second search key that includes the second outbound packet's destination address but does not include any network interface identifier. | 10-11-2012 |
20130035065 | SECURE DEVICE CONFIGURATION PROFILES - A method for configuring a device includes receiving a first configuration profile comprising a first configuration and a first certificate and a second certificate, verifying the first configuration profile with the first certificate, receiving a user input indicating to accept the first configuration profile, configuring the device according to the first configuration, receiving a second configuration profile comprising a second configuration, verifying the second configuration profile with the second certificate and updating the device according to the second configuration, wherein the user is unaware of the updating. | 02-07-2013 |
20130311635 | NETWORK MANAGEMENT - Systems and methods relating to managing network addresses. In one implementation, a method is provided. The method includes sending a first request to use a particular network address, sending one or more second requests for respective hardware addresses corresponding to network addresses of one or more network address leases. When a hardware address corresponding to a particular network address lease is received in response to one of the one or more second requests and an acknowledgement of the first request to use the network address is not received determining whether the network address identified by the lease is the same as the network address in the first request, and when the network address is not the same, sending a third request to use the identified network address corresponding to the lease. | 11-21-2013 |
Patent application number | Description | Published |
20090053706 | DNA METHYLATION MARKERS ASSOCIATED WITH THE CPG ISLAND METHYLATOR PHENOTYPE (CIMP) IN HUMAN COLORECTAL CANCER - Particular aspects confirm the existence of a CpG island methylator phenotype (CIMP) in colorectal cancer, and provide novel validated DNA methylation markers associated with CIMP. Additional aspects provide novel methods and compositions for: determining CIMP status in colorectal cancers, determining the relationship between CIMP status and other molecular features of the cancers (e.g., BRAF mutation, KRAS mutation and MSI status); determining the relationship between CIMP status and other variables (e.g., age, sex, tumor location, family history, race, country of origin, tumor characteristics (including, tumor type, tumor grade, invasive margin characteristics, lymphocyte infiltration characteristics, direct spread, lymph node spread, venous spread and type of residual adjacent polyp, if present)); and determining, between subgroups defined by CIMP status and BRAF mutations, effects of selected risk factors (e.g., body mass index, smoking history, alcohol intake, dietary folate intake, folate metabolic enzyme polymorphisms and history of hormonal use). | 02-26-2009 |
20090136921 | Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen - Particular embodiments provide novel and clinically useful DNA methylation predictors of hormone receptor status, and predictors of response to endocrine (e.g., hormonal) and non-endocrine breast cancer therapy. The ESR1 gene, encoding the estrogen receptor (ER) alpha proved to be the preferred predictor of progesterone receptor (PR) status, while methylation of the PGR gene, encoding PR, was the preferred predictor of ER status. ESR1 methylation outperformed hormone receptor status as a predictor of clinical response in patients treated with antiestroges (e.g., tamoxifen), while promoter methylation of the CYP1B1 gene, encoding a tamoxifen and estradiol metabolizing cytochrome P450, predicted response differentially in tamoxifen-treated and non-treated patients. High levels of promoter methylation of the ARHI gene, encoding a RAS-related small G-protein, were shown to be preferred predictors of better survival in patients who had not received tamoxifen therapy. | 05-28-2009 |
20100124747 | COMPOSITIONS AND METHODS FOR DIAGNOSIS OR PROGNOSIS OF TESTICULAR CANCER - Provided are compositions and methods for diagnosis or prognosis of testicular or male germ-cell derived cancer, comprising: obtaining sperm DNA from a test subject; determining the methylation status of at least one CpG dinucleotide sequence of at least one gene sequence selected from HRAS, NTF3, MT1A, PAX8, DIRAS3, PLAGL1, SFN, SAT2CHRM1, MEST, RNR1, CYP27B1 and ICAM1; and thereby determining or diagnosing testicular or male germ-cell derived cancer. Provided are compositions and methods for identifying agents that cause testicular or male germ-cell derived cancer, comprising: obtaining human ES-cell derived primordial germ cells; contacting the germ cells or descendants thereof, with a test agent; culturing the contacted cells; determining, using a genomic DNA of the sample, the methylation status of at least one CpG dinucleotide sequence of at least one gene sequence selected from the above group; and identifying at least one test agent that causes testicular or male germ-cell derived cancer. | 05-20-2010 |
20120219946 | DNA METHYLATION MARKERS ASSOCIATED WITH THE CPG ISLAND METHYLATOR PHENOTYPE (CIMP) IN HUMAN COLORECTAL CANCER - Particular aspects confirm the existence of a CpG island methylator phenotype (CIMP) in colorectal cancer, and provide novel validated DNA methylation markers associated with CIMP. Additional aspects provide novel methods and compositions for: determining CIMP status in colorectal cancers, determining the relationship between CIMP status and other molecular features of the cancers (e.g., BRAF mutation, KRAS mutation and MSI status); determining the relationship between CIMP status and other variables (e.g., age, sex, tumor location, family history, race, country of origin, tumor characteristics (including, tumor type, tumor grade, invasive margin characteristics, lymphocyte infiltration characteristics, direct spread, lymph node spread, venous spread and type of residual adjacent polyp, if present)); and determining, between subgroups defined by CIMP status and BRAF mutations, effects of selected risk factors (e.g., body mass index, smoking history, alcohol intake, dietary folate intake, folate metabolic enzyme polymorphisms and history of hormonal use). | 08-30-2012 |